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What is Dead (necrosis) is Dead
Osteoradionecrosis Coexists with Adjacent Soft Tissue Injury
SEEING IS BELIEVING
TODAY’S TALK OUTLINE
• A brief introduction of the speaker’s personal medical career with relevance to title of talk
• Review of HBOT timeline
• Review of HBOT as treatment for radiation injury to bone and soft tissue
• Brief review of brain tumor status and cancer        
In general
• Detailed presentation of recent experience with HBOT as treatment for late effects of radiation therapy on brain
• Implications for potential treatment of other and more common conditions based on brain tumor experience
• Thoughts on approaches to off-label use of HBOT in general and for conditions similar in pathophysiology to radiation
injury to brain
• Summation and recommendations
Introducing Myself
1971Completed medical school at Drexel U.
1971-74             Pediatric Residency U. Colorado
1974-76             US Army Medical Corp
1976-78           Fellowship in Pediatric Hematology-Oncology
1978-82             Assistant Professor  Pediatrics UCLA
1982-88             Division Head, Pediatric Hem-Onc. Albany Medical Center
1988-92             Pediatric Neuro-Oncology, U. Colorado 
1992-present    Adult Neuro-Oncology Practice and Program Chair, Center for Brain         and Spinal Tumors, Colorado Neurological 





DRS. GIULIO D’ANGIO AND AUDREY EVANS
`
First Demonstration of Cancer Cured by 
Combination Chemotherapy
DeVita et al, 1986




A Timeline of Hyperbaric Oxygen Medicine
1878 – Subjects of experiments by Paul Bert experience grand mal seizures while exposed to oxygen under pressure; first demonstration of oxygen
toxicity.
1879 – French surgeon J.A. Fontaine builds mobile pressurized operating room. 
1955 – J Churchill Davidson uses high oxygen concentration in pressurized chamber to treat injury from radiation therapy. Ite Boerema uses   
pressurized oxygen to protect patients during cardiac surgery. 
1970s – With invention of cardiopulmonary bypass, HBOT loses momentum; most uses not supported by scientific data
1975 – Undersea and Hyperbaric Medical Society
convenes to write Hyperbaric Oxygen Therapy
1977 – Committee on Hyperbaric Oxygenation recognizes four categories of diseases treatable with HBOT, ranging from those with strong      
supportive data to those without
1985 – Marx publishes first randomized prospective clinical trial demonstrating efficacy of HBOT for prevention of osteoradionecrosis
2012 – Feldmeier et al updates and confirms Marx’s results
2018 – There are 15 approved uses for HBOT including treatment of soft tissue late radiation injury as well as complications of osteoradionecrosis; 
there are at least 2000 HBO facilities in USA (500 UHMS Accredited) vs. 37 in 1976.
Current Status of Neuro-Oncology and Cancer in General
Facts:
1. Primary brain tumors:  About 50,000 per year in USA  (15,000 grade IV, 15,000 grades II and III, 15,000 benign)
2. Metastatic brain tumors (mostly associated with breast cancer, melanoma, renal cancer, and lymphoma)  100,000 per year
3. Most of the above receive radiation therapy
4. Survival is about 2 years for grade IV, 5-10 years for grade III, and at least 20 years for grades I and II 
5. Survival for metastatic cancer much lower, but dramatically improving, especially for melanoma
6. This translates to at least 20,000 brain tumor patients per year at risk for late effects of RT
7. It is estimated that there are >15,000,000 cancer survivors now in USA and increasing
8. 600,000 new cancer diagnoses per year of whom 50% will receive radiation therapy
HBO as Treatment for Radiation Injury 
to Bone and Soft Tissue
Prevention of osteoradionecrosis: a 
randomized prospective clinical trial of 
hyperbaric oxygen versus penicillin
Marx RE, Johnson RP, Kline SN
J Am Dent Assoc 1985
Healing of tooth extractions with HBO 5.4% vs 29.9% without (p=.005)
Hyperbaric oxygen therapy and delayed 
radiation injuries (soft tissue and bony necrosis): 
2012 update. 
Feldmeier JJ
Undersea Hyperb Med, 2012
Confirms previous paper showing benefit
Refutes risk of increasing risk of recurrent malignancy
Outcomes of Radiation Injuries 
Using Hyperbaric Oxygen Therapy: 
An Observational Cohort Study
Neizgoda JA, Serena TE, Carter MJ
Adv Skin Wound Care 2016
Summary of Findings:
1. Data obtained and analyzed on 2538 patients who were treated with HBOT for late 
effects of radiation therapy
2. Informal survey (UHMS) finds that approximately 50% of patients treated with HBOT had 
diagnosis of radiation injury
3. Only randomized clinical trials or cohort studies analyzed
4. Analysis supports use of HBOT as adjunctive treatment of radiation injuries
TYPES OF INJURY (%)
Osteoradionecrosis 33.4
Dermal soft tissue injury          27.5
Cystitis                                          18.6
Proctitis 9.2
Laryngeal radionecrosis 4.8
Cerebral damage                  1.9
Vaginosis 1.7
Colitis                                           1.4
Esophagitis                                   .9
Enteritis                                         .6

SUCCESSFUL USE OF HBOT TO TREAT RADIATION 
ISCHEMIC BRAIN INJURY IN BRAIN TUMOR 
SURVIVORS
EDWARD ARENSON, WALTER VERNON, STEVEN SNIVELY
Background and Rationale
Use of hyperbaric oxygen therapy (HBOT) for radiation injury to bone and soft tissues is an 
approved therapy. 
Its use for the amelioration, however, of soft tissue brain injury from radiation therapy is 
uncommon and not strongly supported in the medical literature. 
Since it is believed and supported through MRI imaging that radiation injury to brain is 
largely a result of small vessel vasculopathy, we treated 27 irradiated and symptomatic 
brain tumor survivors with HBOT in the hopes of inducing neo-angiogenesis
RATIONALE FOR USE OF HBOT TO TREAT LATE 
RADIATION INJURY TO BRAIN
As opposed to non-radiation-induced soft tissue injury, in which there
is a sharp distinction between injured and healthy tissue, radiated
tissue has an an indistinct boundary and inadequate oxygen gradient
to induce neo-angiogenesis. HBOT amplifies the gradient 7-10 fold
(2.4ATM) which induces robust neo-angiogenesis.
Knighton DR et al,  Surgery, 1981
Superior Tissue Delivery Of Dissolved vs. Hemoglobin-Bound Oxygen

Materials and Methods
Initially, we treated patients at 2.0 ATM and used 30-40 treatments. These were
predominantly patients who had their radiation therapy more than 100 months before HBOT.
We saw no unexpected adverse effects, so we increased the pressure on the remaining
patients to 2.4 ATM in order to maximize efficacy while avoiding air breaks and also























RESPONSE vs. MEDIAN NUMBER OF 
DIVES
RESPONDERS
Median # of Treatments              40




RESPONSE vs. MEDIAN AGE (YEARS)
RESPONDERS NON-RESPONDERS
40                                                         62
CASE HISTORY
55yo woman treated at age 12 for childhood leukemia with
prophylactic whole brain radiation therapy. One of first patients to be
cured. Recent rapid loss of peripheral visual fields in a pattern
consistent with late optic radiation vasculopathy. No other cause
identified. Visual field results after 48 of 60 planned treatments of HBO.
RT EYE
Before HBO After HBO
LEFT EYE
Before HBO After HBO
Cerebrovascular Disease with Atrophy
Cerebrovascular Disease with          
Atrophy 
CONCLUSIONS
1. HBOT was safe in irradiated brain tumor survivors at 2.4 ATM without air
breaks and was not observed to increase risk or frequency of seizures.
2. No patient who received HBOT in this clinical setting experienced
worsening of neurological function or MRI evidence of progressive
vasculopathy.
3. Sixty-eight per cent of treated patients experienced either combined
clinical and radiographic benefit (n=16) or only radiographic improvement
(n=1).
4. All of the 32% of patients who did not improve after HBOT, save two relatively
elderly patients, were treated more than 100 months post RT. This observation
is highly statistically significant. If we exclude those patients whose HBOT was
initiated more than 100 months after RT, the response rate was 89%. (This level
of response is similar to levels achieved in other anatomical sites in recent
review by Niezgoda et al)
5. A broad spectrum of clinical symptoms were observed to improve in selected
patients including fatigue, memory, multi-tasking, navigation, executive
function, somnolence, motor dysfunction and seizure control. This was
demonstrated both by clinical observation and repeat neuro-cognitive testing.
HBOT in this unique group of patients is surprisingly effective
and deserves more study to better define its optimum
application. It is notable that areas of brain remote from the
field of radiation demonstrated improved vascularity after
HBOT which suggests that some clinical improvement might
be attributable to amelioration of vascular disease
unrelated to RT.
Ischemic Radiation Brain Injury may be
the Only Chronic Brain Condition for which
there is a Treatment (HBOT) which Provides
Demonstrable and Durable Improvement
Rather than Temporary Control
LEVELS OF CLINICAL EVIDENCE 
HIERARCHY
• Meta-Analysis of multiple randomized clinical trials, 
preferably double-blinded
• Single randomized clinical trial, preferably blinded
• Cohort Studies
• Retrospective reviews
• Anecdotes of limited numbers of patients
• Multiple patients serving as their own controls (usually 
not listed as valid)
A Few Conditions Similar in Pathophysiology to Radiation Injury of Brain
(in which there are symptomatic areas of ischemia without necrosis or loss of 
neurons or nerves)
• Any form of vascular dementia, i.e. hypertension, hyperlipidemia, diabetic, 




• Avascular necrosis of hip, knee, etc. 
• Small vessel peripheral vascular disease
• Lyme disease
Hyperbaric Oxygen Therapy Has a 
Bright Future BUT……….
Indiscriminate Use Without Strong Supporting 
Evidence and Careful Attention to 
Demonstration of Benefit Jeopardizes Its Future
The experimental model of using meticulously evaluated patients as their own
controls, especially when the response to treatment is quantifiable, e.g. color
perfusion, may be the best choice for establishing the benefit of new applications
of HBO. (Seeing is believing)
All Irradiated Brain Tumor Survivors Are At Risk for 
Radiation Vascular Injury and Should be 
Monitored Carefully and Treated Early With HBOT 
HOW EARLY?

